1. Home
  2. DSGN vs CPSS Comparison

DSGN vs CPSS Comparison

Compare DSGN & CPSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • CPSS
  • Stock Information
  • Founded
  • DSGN 2017
  • CPSS 1991
  • Country
  • DSGN United States
  • CPSS United States
  • Employees
  • DSGN N/A
  • CPSS N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • CPSS Finance: Consumer Services
  • Sector
  • DSGN Health Care
  • CPSS Finance
  • Exchange
  • DSGN Nasdaq
  • CPSS Nasdaq
  • Market Cap
  • DSGN 224.8M
  • CPSS 193.8M
  • IPO Year
  • DSGN 2021
  • CPSS 1992
  • Fundamental
  • Price
  • DSGN $3.98
  • CPSS $9.02
  • Analyst Decision
  • DSGN Hold
  • CPSS
  • Analyst Count
  • DSGN 1
  • CPSS 0
  • Target Price
  • DSGN $4.00
  • CPSS N/A
  • AVG Volume (30 Days)
  • DSGN 91.9K
  • CPSS 12.5K
  • Earning Date
  • DSGN 05-07-2025
  • CPSS 05-12-2025
  • Dividend Yield
  • DSGN N/A
  • CPSS N/A
  • EPS Growth
  • DSGN N/A
  • CPSS N/A
  • EPS
  • DSGN N/A
  • CPSS 0.79
  • Revenue
  • DSGN N/A
  • CPSS $188,776,000.00
  • Revenue This Year
  • DSGN N/A
  • CPSS $146.82
  • Revenue Next Year
  • DSGN N/A
  • CPSS $18.24
  • P/E Ratio
  • DSGN N/A
  • CPSS $11.45
  • Revenue Growth
  • DSGN N/A
  • CPSS N/A
  • 52 Week Low
  • DSGN $2.60
  • CPSS $7.85
  • 52 Week High
  • DSGN $7.77
  • CPSS $12.73
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 53.86
  • CPSS 50.32
  • Support Level
  • DSGN $3.67
  • CPSS $8.78
  • Resistance Level
  • DSGN $4.13
  • CPSS $9.15
  • Average True Range (ATR)
  • DSGN 0.30
  • CPSS 0.28
  • MACD
  • DSGN 0.05
  • CPSS -0.01
  • Stochastic Oscillator
  • DSGN 85.78
  • CPSS 31.94

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

Share on Social Networks: